Abcam Plc Exceeds Expectations

Growth is on track at Abcam Plc (LON: ABC); is there a bargain here?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Every investor’s heart flutters when a company releases an ‘exceeding expectations’ statement, and that is exactly what AIM-listed protein research tool supplier Abcam (LSE: ABC) did this morning. Overall, second-half sales are up around 10%, and the firm’s new China operation delivered an exciting 20% year-on-year revenue growth in the final quarter of Abcam’s trading year.

The market likes it. Abcam shares are up almost 6% on yesterday’s close at 380p, as I write, providing welcome relief to existing shareholders who’ve clung on while the shares slipped from the 520p they achieved in early 2014.

Hang on — the share price is well down from its highs and the latest market update is positive. I can feel my growth-at-a-reasonable-price receptors twitching!

Picks and shovels for scientists

If you’ve ever invested in the wild frontier of biotechnology or pharmaceutical development, you’ll know that hunting for the next blockbuster drug often involves putting your money into profitless research firm’s with a propensity to gobble cash as scientists beaver away hunched over their test tubes.

The most frequent outcome in the early stage life science sector seems to be that firm’s host a series of fundraisings that dilute investors’ interests into insignificance, making any eventual commercial gain meaningless to long-suffering shareholders. Such companies also have a propensity for going bust, which means total loss of investment.

Wouldn’t it be good to invest in a company that supplies the tools that this army of scientists needs to carry out their research, thus investing in the industry as a whole, rather than taking a mad punt on any one pie-in-the-sky investment story? Well we can, with Abcam.

Abcam produces and distributes protein research tools that enable life scientists to analyse components of living cells at the molecular level, which is an essential part of understanding health and disease. The firm’s vision is to create the world’s leading life science reagents company.

Amongst other things, the firm supplies a neat line in Monoclonals, Polyclonals and Conjugated Primary Antibodies – manna from heaven for any self-respecting research scientist needing high performance products with detailed technical specifications; which means most of them.

Driving growth

Abcam’s growth strategy aims for both organic and acquisitive progress and, as with any decent growth proposition, the firm focuses on quality, cost-control, and delivering operations as close to excellent as it can.

The formula has seen some success:

Year to June 2009 2010 2011 2012 2013
Revenue (£m) 57 71 83 98 122
Net cash from operations (£m) 15 20 25 24 39

That’s impressive-looking growth, but Abcam’s acquisition strategy means that fund-raising along the way has diluted investors’ interests to some extent.

Valuation

At a share price of 379p, Abcam trades on a P/E rating of about 21 and the shares yield a dividend of around 2.2%. Based on what we know, I think the firm is worth further research. We’ll find out more with the full-year results due on 9 September 2014.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

The FTSE 100 is on fire! Yet these 2 stocks still look cheap to me

Despite the FTSE 100 hitting record highs, there’s no shortage of undervalued opportunities across the index, says Ben McPoland.

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Greggs shares: an outstanding bargain after crashing nearly 40%?

Shares of one-time market darling Greggs have been in foul form recently. But is this a once-in-a-blue-moon opportunity for our…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

This FTSE 100 stock’s suddenly become the highest-yielder on the index!

The league table of FTSE 100 (INDEXFTSE:UKX) dividend stocks has a new number one. But our writer explains why there…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

Is this under-the-radar UK stock as cheap as its rooms?

Our writer’s been keeping an eye on a little-known UK stock that operates in a niche, but profitable, sector of…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

It’s a ‘Fabulous Friday’ for holders of these FTSE 100 shares!

Four members of the FTSE 100 (INDEXFTSE:UKX) are making their latest dividend payments today (11 July). Our writer takes a…

Read more »

Man riding the bus alone
Investing Articles

Check out this spectacular FTSE 250 stock

UK investors willing to look beyond the FTSE 100 can find some outstanding companies. Online advertising business Baltic Classifieds might…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

The JD Sports share price is down 18% in a year. And the stock’s only yielding 1.1%. Here’s what I’m doing…

With the JD Sports share price struggling and a tiny dividend on offer, there doesn’t appear to me much going…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How long would it take an owner of Legal & General shares to get their money back in passive income?

Our writer looks at the passive income potential of Legal & General, one of the highest-yielding shares on the FTSE…

Read more »